Special Situation: Control Is Becoming the Category

Issued on Behalf of Doseology Sciences Inc.

In 2022, Philip Morris International made a defining strategic move by acquiring Swedish Match, the maker of ZYN, for approximately US$16 billion.[1]

Headlines focused on nicotine at the time. However, the broader implication was about delivery.

The acquisition proved that delivery platforms themselves, not just ingredients, can become strategically valuable assets.

These platforms are designed around discretion, portability, and repeat daily use. They integrate into everyday routines rather than disrupting them.

Consumer behavior has shifted since then. Energy drinks, vapes, and pills are being reassessed. The market is moving toward formats that emphasize moderation, simplicity, and control.

One micro-cap company has now entered that conversation.

That company is…

Doseology Sciences Inc.

CSE: MOOD | OTCPK: DOSEF | FSE: VU70

The Market Disconnect

Investors are currently looking at a disconnect between perception and reality.

The Perception: A Canadian-listed micro-cap historically associated with a prior operating focus.
The Reality: An emerging S.-oriented oral delivery platform led by former executives from Philip Morris, JUUL, and highly successful retail ventures.

Why the Gap Exists

Micro-cap limitations: Current market cap (~C$6M) limits institutional visibility.
Recent Pivot: Announced in March 2025[2], meaning market awareness is still forming.
Stage of Development: The company is in the platform validation stage. This naturally precedes scale or mainstream analyst coverage.

Key Takeaway: The current trading profile reflects historical context rather than the company’s evolving platform ambition

The Thesis: Control First.
Powered by Doseology.

Legacy delivery systems like energy drinks and vapes were built for volume and velocity. The next generation is being shaped around fit, routine, and discretion.

Doseology is not positioning a single product. It is evaluating a platform.

Using buccal and sublingual delivery (absorbed through the oral mucosa), Doseology is building a format-level advantage.

Bypasses the gut: Reduces reliance on sugars, liquids, or fillers.
Offers Control: Supports predictable, measured use.
Fits the Routine: Creates discreet formats that align with modern regulatory expectations.

The Strategy: Prioritize delivery mechanics over ingredient hype. Focus on repeatable formats rather than one-off SKUs.

The Business Model: “Powered by Doseology™”

Beyond internal development, Doseology is building a platform-enabled go-to-market funnel.

Think of this as an Innovation Layer for the industry. Through “Powered by Doseology,” the company intends to enable emerging brands, influencers, and functional product developers to:

Access oral delivery R&D and formulation insight.
Leverage compliant operating infrastructure.
Test consumer response before large-scale deployment.

This positions Doseology as a scalable platform and commercialization partner, not just a brand owner.

The Categories Converging on This Format:

Nicotine Pouches: ~$5.4B (2024) → $25B+ (2030)[3]
Energy/Functional Stimulants: ~$79B → $125B by 2030[4]
Nootropics: ~$11B by decade-end[5]

The “Why Now” Context: Stage, Not Outcome

Why do some investors look for early platforms? Large incumbents typically engage only after formats are proven, regulated, and widely adopted.

Doseology operates earlier on that same continuum.

Philip Morris (ZYN): Downstream participation in a validated, scaled category.
Doseology: Platform formation stage, where value is driven by execution milestones rather than volume.

This comparison reflects a difference in stage, not an equivalence of scale or outcome.

Management: Built for Execution

Doseology is led by operators who have created value by recognizing consumer behavior shifts early and executing within regulated environments.

Chris Jackson, CEO & Director

Founder, Qtrade Financial Group: Built and sold to Desjardins[6]. An expert in building platforms that offer transparency and control.
Role: Sets platform direction and capital allocation.

Timothy Corkum, President & COO

Former President, JUUL Labs Canada: Led national operations during rapid consumer adoption.[7]
Former Philip Morris International: Held senior commercial roles in reduced-risk categories.
Role: Oversees day-to-day operations and regulatory alignment.

Joseph Mimran, Strategic Advisor

The Retail Titan: Founder of Club Monaco, Creator of Joe Fresh, and former Dragon on Dragons’ Den.
The Signal: Doseology acquired the brand Feed That Brain from Mimran’s portfolio[8]. He remains involved to advise on when emerging formats are ready for mainstream retail.

Patrick W. Sills, Go-to-Market Advisor

Background: Former PMI and Fontem Ventures. He had exposure to the early emergence of modern oral nicotine pouch formats.[9]

Execution Roadmap: The Florida Beachhead

Rather than treating the U.S. as a future goal, Doseology moved directly to execution.

Doseology USA Inc. (Florida): Established March 2025.[10]
Purpose: To support the development, manufacturing coordination, and commercialization of oral delivery products for the American market.
Why Florida: Offers access to Southeast distribution corridors and proximity to national logistics infrastructure.

The Bottom Line

Better-for-you is no longer just about what is inside the product. It is about how the product fits into real life.

Doseology is building the delivery layer for that shift.

Capital Efficient: ~$900,000 cash and zero debt as of April 2025.[11]
Structure: ~8 million shares outstanding.
Focus: A platform strategy extending beyond a single product or ingredient.

Control First. Powered by Doseology.

QUICK FACTS

Company: Doseology Sciences Inc.
Tickers: CSE: MOOD | OTCPK: DOSEF | FSE: VU70
Shares Outstanding (as of August 2025): ~8 million
Recent Financing Terms: $0.225 per unit (June 2025), warrants at $0.50
Cash Position (as of April 2025): Approximately $900,000
Debt: Zero
Canadian Retail Footprint: 500+ locations
Headquarters: Kelowna, British Columbia
U.S. Operations: Doseology USA Inc., Florida

This Is Where It Starts

Before mainstream coverage. Before institutional visibility. Before the category has a name.

If the thesis resonates, the next step is yours.

Visit Doseology Investors →

CSE: MOOD | OTCPK: DOSEF | FSE: VU70

Control First. Powered by Doseology.

DISCLAIMER:

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity-Insider.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Doseology Sciences Inc. advertising and digital media from USA News Group (“the Company”). There may be 3rd parties who may have shares of Doseology Sciences Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Doseology Sciences Inc., which were purchased as a part of a private placement. MIQ will not buy or sell shares of Doseology Sciences Inc.for a minimum of 72 hours from the publication date on this website (December 16, 2025), but reserve the right to buy and sell, and will buy and sell shares of Doseology Sciences Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely carefulBe extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES CITED:

[1] https://www.pmi.com/media-center/news/pmi-progresses-toward-sole-ownership-of-swedish-match

[2] https://doseology.com/2025/03/04/doseology-invests-into-the-multi-billion-dollar-u-s-modern-oral-stimulant-market/

[3] https://www.grandviewresearch.com/industry-analysis/nicotine-pouches-market-report

[4] https://www.grandviewresearch.com/industry-analysis/energy-drinks-market

[5] https://www.researchandmarkets.com/reports/5751844/nootropics-market-report

[6] https://www.thenewswire.com/press-releases/1L5PFGorO-doseology-appoints-chris-jackson-founder-of-qtrade-as-chief-executive-officer-and-a-director.html

[7] https://doseology.com/2025/06/17/doseology-appoints-timothy-corkum-as-president-coo-to-drive-strategic-expansion-into-the-stimulant-pouch-market/

[8] https://doseology.com/2025/08/19/doseology-completes-acquisition-of-feed-that-brain/

[9] https://www.thenewswire.com/press-releases/1k98F4lGa-doseology-appoints-patrick-w-sills-as-strategic-go-to-market-advisor.html

[10] https://doseology.com/2025/03/04/doseology-invests-into-the-multi-billion-dollar-u-s-modern-oral-stimulant-market/

[11] https://doseology.com/2025/04/28/doseology-announces-1-2m-private-placement-to-advance-commercialization/